| Parent company | Bayer |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2025 |
| Capital investment ($): | 43.6 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Myerstown |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | OTC Drugs |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity, Lean/other business process improvement techniques |
